lung cancer best timed pathway · @gmceducation i lung cancer challenges •poor outcomes compared...

18
Lung Cancer Best Timed Pathway Greater Manchester’s approach Dr Seamus Grundy Consultant Respiratory Physician Salford Royal © Copyright Greater Manchester Cancer. All rights reserved.

Upload: others

Post on 04-Jul-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Lung Cancer Best Timed Pathway

Greater Manchester’s approach

Dr Seamus Grundy

Consultant Respiratory Physician

Salford Royal

© Copyright Greater Manchester Cancer. All rights reserved.

Page 2: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

Overview

• National and Regional ‘best timed pathways’

• GM Cancer Project

Page 3: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

Lung Cancer: The Facts

Page 4: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

Current National Targets

https://www.nuffieldtrust.org.uk/news-item/cancer-waiting-times-how-has-nhs-performance-changed-over-time

Target: 85%

Target: 93% Target: 96%

Page 5: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

Lung Cancer Challenges

• Poor outcomes compared with European Countries

• Significant variation in practice/outcomes

• Failure to meet NHS England Cancer Targets

• RCT evidence that shorter diagnostic pathways associated with significantly improved long term outcomes

Page 6: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

62 day performance Q1 19/20

0

10

20

30

40

50

60

70

80

90

Bolton Pennine East Cheshire WWL Stockport Salford Tameside MFT GM

Page 7: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

National ‘Optimal’ Pathway

Triaging Test

Page 8: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

National ‘Optimal’ Pathway

Staging/Diagnostic tests

Clinical Triage/ Filter out non-cancer

MDT discussion

Page 9: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

National ‘optimal’ pathway

Page 10: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

National ‘optimal’ pathway

• 52 day pathway

• Taken a ‘pragmatic approach’ to timings

• Sets out clear principles with which to work

• But is 52 days really ‘optimal’?

(Optimal: adj. best or most favourable)

Page 11: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

GM ‘Optimal’ Lung Pathway

Page 12: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Greater Manchester Cancer

GM Optimal Lung Pathway

Page 13: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

Standardised staging bundles

Page 14: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

GM Cancer Best timed Pathway Project

• Resource Gap Analysis

• Investment of £1.3M

• Clinical Leadership with Project Management Support

Page 15: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

GM Cancer Best timed Pathway Project

• Invested in all Secondary care trusts in GM & East Cheshire + specialist treatment centres

• Pathway Navigators (9 across GM)

• Specialist Nurses (11 across GM)

• Clinical Fellows (1 @ MFT)

• Point of care eGFR testing

Page 16: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

GM Cancer Best timed Pathway Project

Outcome measures:

• Complete achievement of 62 day standard

• 90% staging CT within 72 hrs of referral

• 80% discussed at MDT by day 21

• Reduced median time from referral to treatment

Page 17: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

@GMCEducation I

Lessons Learnt

• Prompt access to initial ‘diagnostic test’ essential

• Immediate Specialist triaging • Job planned ‘virtual DCC’

• Thorough resource gap analysis

• Pathway Navigators are key to success

Page 18: Lung Cancer Best Timed Pathway · @GMCEducation I Lung Cancer Challenges •Poor outcomes compared with European Countries •Significant variation in practice/outcomes •Failure

Q&A

© Copyright Greater Manchester Cancer. All rights reserved.